Back in the fall of 2017 the International Coalition of Medicines Regulatory Authorities (ICMRA) published a paper containing recommendations for pharmaceutical product regulators around the world to consider for achieving future interoperability of national or market pharma track and trace systems. That is, their recommendations were aimed at enabling interoperability between and among the various current and future pharma track & trace regulated systems around the globe. For example, their recommendations could help the US FDA exchange and accept information from the European Medicines Verification System (EMVS), and vice versa. In this way, regulators in each market could learn about problems with drug products circulating within each other’s markets. Why would you want to do such a thing? Let’s take a look at their 2017 paper.
…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance
DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of RxTrace. The material contained in RxTrace is not legal advice. The writers of RxTrace are not lawyers. The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating the positions of any company, organization or individual other than RxTrace.